Anti-epileptic medication and bone health
- First Online:
- 683 Downloads
Epilepsy is a common chronic neurological disorder, usually requiring long-term treatment with anti-epileptic drugs (AED). Many studies have reported that AED therapy is associated with metabolic bone disease and is a major iatrogenic risk factor for fractures. There remains uncertainty about the type(s) of bone disease due to AED treatment, and the pathogenesis of AED-associated fractures.
Deficits in bone mineral density (BMD) are widely reported in AED-treated patient populations. However, much of the research conducted to date has been limited by factors such as small sample size, potentially biased subject selection, a lack of selection of appropriate control data, and failure to take account of important confounding influences. The pathogenesis of AED-associated fractures is likely to be multifactorial, due to factors including reduced BMD, impaired bone quality (due to osteoporosis and/or osteomalacia), increased propensity to fall, and fractures associated with seizures or loss of consciousness.
Patients receiving long-term AED should be monitored for indices of bone health, including BMD and vitamin D status. Lifestyle factors should be optimized, vitamin D status maintained, and fall prevention strategies introduced as appropriate. Good seizure control is important. The use of additional, specific osteoporosis therapy is not evidence-based in this setting, but would appear reasonable in patients with clinically significant decreases in BMD, applying current treatment guidelines for osteoporosis.
There is a pressing need for improved understanding of the pathogenesis of AED-associated bone disease, for better definition of the risk associated with specific AED regimens, and for the development of evidence-based preventive and treatment approaches in this common but neglected disorder.
KeywordsAnti-epileptic drugs Bone mineral density Epilepsy Falls Fractures Metabolic bone disease
- 4.Schmid F (1967) Osteopathien bei antiepileptischer Dauerbehandlung. Fortschr Med 85:381–382Google Scholar
- 41.Valimaki MJ, Tiihonen M, Laitinen K, Tahtela R, Karkkainen M, Lamberg-Allardt C, Makela P, Tunninen R (1994) Bone mineral density measured by dual-energy x-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs. J Bone Miner Res 9(5):631–637PubMedCrossRefGoogle Scholar
- 48.Wark JD, Larkins RG, Perry-Keene D, Peter CT, Ross DL, Sloman JG (1979) Chronic diphenylhydantoin therapy does not reduce plasma 25-hydroxy-vitamin D. Clin Endocrinol (Oxf) 11(3):267–274Google Scholar
- 50.Shane E (1996) Osteoporosis associated with illness and medications. In: Marcus R, Feldman D, Kelsey J (eds) Osteoporosis. Academic Press, New YorkGoogle Scholar
- 60.Collins N, Maher J, Cole M, Baker M, Callaghan N (1991) A prospective study to evaluate the dose of vitamin D required to correct low 25-hydroxyvitamin D levels, calcium, and alkaline phosphatase in patients at risk of developing antiepileptic drug-induced osteomalacia. Q J Med 78(286):113–122PubMedGoogle Scholar